Home    Back

Rilzabrutinib    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
300IgG4-related disease1

300. IgG4-related disease    [ 31 clinical trials,   33 drugs,   (DrugBank: 16 drugs),   11 drug target genes,   81 drug target pathways]
Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 31 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04520451
(ClinicalTrials.gov)		August 21, 202011/8/2020Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease PatientsAn Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related DiseaseIgG4-Related DiseaseDrug: rilzabrutinib;Drug: GlucocorticoidsPrincipia Biopharma Inc.Massachusetts General HospitalRecruiting18 YearsN/AAll25Phase 2United States